Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate
- 9 May 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 21 (7), 1227-1235
- https://doi.org/10.1158/1535-7163.mct-22-0013
Abstract
Antibody–drug conjugates (ADC) represent a fast-growing drug class in oncology. However, ADCs are associated with resistance, and therapies able to overcome it are of utmost importance. Recently, enfortumab vedotin-ejfv (EV) was approved in nectin-4+ metastatic urothelial cancer. We previously described PVRL4/nectin-4 as a new therapeutic target in breast cancer and produced an efficient EV-like ADC comprising a human anti–nectin-4 mAb conjugated to monomethyl auristatin-E (MMAE) named N41mab-vcMMAE. To study the consequence of the long-term treatment with this ADC, we developed a preclinical breast cancer model in mice, and report a mechanism of resistance to N41mab-vcMMAE after 9-month treatment and a way to reverse it. RNA-sequencing pointed to an upregulation in resistant tumors of ABCB1 expression, encoding the multidrug resistance protein MDR-1/P-glycoprotein (P-gp), associated with focal gene amplification and high protein expression. Sensitivity to N41mab-vcMMAE of the resistant model was restored in vitro by P-gp pharmacologic inhibitors, like tariquidar. P-gp is expressed in a variety of normal tissues. By delivering the drug to the tumor more specifically than classical chemotherapy, we hypothesized that the combined use of ADC with P-gp inhibitors might reverse resistance in vivo without toxicity. Indeed, we showed that the tariquidar/N41mab-vcMMAE combination was well tolerated and induced a rapid regression of ADC-resistant tumors in mice. In contrast, the tariquidar/docetaxel combination was toxic and poorly efficient. These results show that ABC transporter inhibitors can be safely used with ADC to reverse ADC-induced resistance and open new opportunities in the fight against multidrug resistance.Keywords
Other Versions
Funding Information
- Ligue Nationale Contre le Cancer (EL2016.LNCC/DaB, EL2019.LNCC/FB)
This publication has 31 references indexed in Scilit:
- A role for PVRL4-driven cell–cell interactions in tumorigenesiseLife, 2013
- Nectin 4 Overexpression in Ovarian Cancer Tissues and SerumAmerican Journal of Clinical Pathology, 2010
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival OutcomesClinical Cancer Research, 2009
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung CancerCancer Research, 2009
- Integrated Profiling of Basal and Luminal Breast CancersCancer Research, 2007
- Nectin-4 is a new histological and serological tumor associated marker for breast cancerBMC Cancer, 2007
- Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinomaCancer, 2005
- Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiersLeukemia, 2002
- Nectin4/PRR4, a New Afadin-associated Member of the Nectin Family That Trans-interacts with Nectin1/PRR1 through V Domain InteractionOnline Journal of Public Health Informatics, 2001